Since most of CRC cell lines harbor mutations in different genetic components of the Wnt/β-catenin pathway that constitutively activate the pathway, we evaluated whether these cells were responsive to treatment using Wnt3a, a ligand of this signaling pathway. Here, WNT3A is linked to colorectal carcinoma.